2Chandra J, Kuhn DM, Pranab K, et al. Biofihn formation by the fungal pathogen candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183:5385 - 5394.
3Nguyen MH, Peacock JE Jr, Tanner DC. et al, Therapeutic approaches in patients with candidemia: Evaluation in a multicenter,prospective, observational study, Arch Int Med 1995 ; 155 : 2429 -2435.
4Baillie GS, Douglas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicro Chemother 2000 ;46: 397 - 403.
5Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro, Infect Immunol 1994;62:915 - 921.
6Hawser SP, Baillie GS, Douglas LJ. Production of extracellular matrix by Candida albicans biofilms, J Med Microbiol 1998;47:253-256.
7Baillie GS, Douglas IJ. Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 1999 ; 48 : 671 - 679.
8Ramage G, VandeWalle K, Lopez- Ribot JL, et al, The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans.FEMS Microbiol Lett 2002;214:95 - 100.
9Kuhn DM, Chandra J, Mukherjee PK, et al. Comparison of Biofilms Formed by Candida albicans and Candida parapsilosis on Bioprosthetic Surfaces, Infect Immun 2002;70:878- 888.
10Hawser SP, Douglas LJ. Resistance of Candida albicans Biofilms to Antifungal Agents In Vitro. Antimicrob Agent Chemother 1995;39:2128 - 2131.
